[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"valvular-heart-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:valvular-heart-disease":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,31,0,25,[9,40,66,119,140,173,203,233,256,278,309,354,382,400,426,457,476,500,524,547,568,589,617,643,667],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100630094","a-study-of-clinical-implications-of-pulmonary-vascular-disease-in-valvular-heart-disease-100630094",false,"NCT07483203","A Study Of Clinical Implications Of Pulmonary Vascular Disease In Valvular Heart Disease","Clinical Implications of Pulmonary Vascular Disease in Valvular Heart Disease","Inclusion Criteria:\n\n* ≥18 years old; AND\n* Scheduled for valve procedures\n\nExclusion Criteria:\n\n* Congenital heart disease (except for bicuspid aortic valve), OR\n* Carcinoid heart disease, OR\n* Valvular mass, OR\n* Endocarditis, OR\n* Any other condition that, in the opinion of the investigator, would impair their ability to complete the study","ALL","18 Years",{"count":20,"type":21},600,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to characterize pulmonary hemodynamic profiles, with a focus on PVR subtypes, in patients with left-sided valvular heart disease undergoing aortic or mitral valve intervention, and to identify patterns predicting reversibility of TR and RV dysfunction.",[25,26],"Pulmonary Vascular Disease","Valvular Heart Disease","RECRUITING","2026-06-16",{"date":30,"type":31},"2026-06-18","ACTUAL",{"date":33,"type":31},"2026-04-28",{"date":35,"type":21},"2028-05",{"name":37,"class":38},"Mayo Clinic","OTHER",1,{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":49,"studyType":22,"phases":4,"briefSummary":50,"conditions":51,"keywords":52,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100606511","multivalve--a-prospective-multicentre-study-of-multiple-and-mixed-valvular-heart-disease-100606511","NCT07176507","MULTIVALVE : A Prospective Multicentre Study of Multiple and Mixed Valvular Heart Disease","MULTIVALVE","Inclusion Criteria:\n\n* Age ≥18 years\n* The patient has been informed of the study and has not refused to participate.\n* An echocardiographic diagnosis of MMVD is defined as having at least two moderate to severe valvulopathies, as assessed by a cardiologist using transthoracic echocardiography (TTE), on one or more valves. This is in line with the recommendations of the ESC, the ASE, and expert opinion.\n\nExclusion Criteria:\n\n* History of valve surgery or percutaneous valve intervention involving the valve in question.\n* A history of infective endocarditis, whether treated surgically or not, confirmed according to the modified Duke criteria.\n* Acute infective endocarditis at the time of evaluation for inclusion, confirmed according to the modified Duke criteria.\n* Complex congenital heart disease.\n* Patients who are already included in the European EACVI-MMVD study.\n* Pregnant women\n* Patients not affiliated to social security\n* Patients who are minors\n* Patients under guardianship, curatorship or judicial supervision\n* Patients who refuse to participate in this register.",{"count":48,"type":21},1000,"5 Years","Multiple and mixed valvular heart disease (MMVD) is a common condition in clinical practice. It corresponds to a combination of stenotic or leaky lesions on two or more heart valves (multiple valve disease), or a combination of stenotic and leaky lesions on the same valve (mixed valve disease). However, the management of their clinical, biological and cardiovascular imaging is not well established. Current European Society of Cardiology (ESC) recommendations primarily address the various valve diseases in isolation. This results in an absence of reliable recommendations for managing MMVD, with different approaches being adopted by care centres.\n\nIn order to address this knowledge gap regarding MMVD, it is crucial to assess its prevalence, the cardiovascular imaging methods employed and the management strategies, as well as to identify prognostic factors for the various combinations of valve disease.\n\nThe multicentre MMVD study will be a valuable resource as it will improve our understanding of the prognosis for patients with MMVD. It will highlight imaging and biological markers associated with the prognosis of different combinations of MMVD.",[26],[53,54,55],"valvular heart disease","Multiple and mixed valvular heart disease","multiple valve disease","2026-06-11",{"date":58,"type":31},"2026-06-12",{"date":60,"type":31},"2025-10-30",{"date":62,"type":21},"2032-10",{"name":64,"class":38},"French Cardiology Society",2,{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":77,"conditions":78,"keywords":93,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":118},"100569808","ai-enabled-direct-from-ecg-ejection-fraction-ef-severity-assessment-using-cor-ecg-wearable-monitor-100569808","NCT06699056","AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor","AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Using COR ECG Wearable Monitor","EFACT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Able and eligible to wear a Holter monitor\n\nExclusion Criteria:\n\n* Receiving mechanical respiratory or circulatory support, or renal support therapy, at the time of screening or during Visit #1\n* Any condition that, in the investigator's opinion, could interfere with compliance with the study protocol or pose a safety risk to the participant\n* History of poor tolerance or severe skin reactions to ECG adhesive materials",true,{"count":76,"type":21},2000,"This prospective, multicenter, cluster-randomized controlled study aims to evaluate the accuracy of an investigational artificial intelligence (AI) Software as a Medical Device (SaMD) designed to compute ejection fraction (EF) severity categories based on the American Society of Echocardiography's (ASE) 4-category scale. The software analyzes continuous ECG waveform data acquired by the FDA-cleared Peerbridge COR® ECG Wearable Monitor, an ambulatory patch device designed for use during daily activities. The AI software assists clinicians in cardiac evaluations by estimating EF severity, which reflects how well the heart pumps blood.\n\nIn this study, EF severity determination will be made using 5-minute ECG recordings collected during a 15-minute resting period with participants seated upright. The results will be compared to EF severity obtained from an FDA-cleared, non-contrast transthoracic echocardiogram (TTE) predicate device. This comparison aims to validate the accuracy of the AI software.",[79,80,81,82,83,84,26,85,86,87,88,89,90,91,92],"Ventricular Ejection Fraction","LVF","LV Dysfunction","Atrial Enlargement","Conduction Defect","Heart Failure","Ischemic Heart Disease","Cardiotoxicity","Myocardial Infarction","Dilated Cardiomyopathy","HFrEF - Heart Failure With Reduced Ejection Fraction","HFpEF - Heart Failure With Preserved Ejection Fraction","Syncope","Remodeling, Cardiac",[94,95,96,97,98,99,100,81,101,102,103,104,105,106,82,107],"ECG Patch","LVEF","Holter","ECG Wearable","COR","Atrial Conduction","ECG Biomarker","SaMD","Clinical Decision Support","ECG","EF Severity","Ejection Fraction","AI","Electrical Remodeling","2026-05-28",{"date":110,"type":31},"2026-06-01",{"date":112,"type":31},"2024-11-21",{"date":114,"type":21},"2027-11-15",{"name":116,"class":117},"Peerbridge Health, Inc","INDUSTRY",8,{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":74,"sex":17,"minAge":18,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":4},"100637624","diagnostic-study-of-structural-heart-disease-based-on-cardiac-electromechanical-signals-100637624","NCT07603115","Diagnostic Study of Structural Heart Disease Based on Cardiac Electromechanical Signals","Inclusion Criteria:\n\n* \\- Aged ≥ 18 years.\n* For the case group: Presence of valvular lesions confirmed by transthoracic echocardiography.\n* For the control group: Normal cardiac valves and no evidence of other cardiovascular diseases confirmed by transthoracic echocardiography.\n* Ability to undergo and complete speckle tracking echocardiography.\n\nExclusion Criteria:\n\n* Patients who are unwilling to participate in this study.\n* Patients with a known allergy to the electrode patches or medical adhesive tapes used in this study.\n* Patients who are unable to cooperate with the completion of required examinations.\n* Patients with incomplete clinical or imaging data that cannot be supplemented.","85 Years",{"count":127,"type":21},1300,"Study participants will be prospectively recruited from consecutive outpatient and inpatient populations presenting to the Cardiology and Cardiac Surgery Departments of the following participating institutions: The First Affiliated Hospital of Xi'an Jiaotong University, The Second Affiliated Hospital of Xi'an Jiaotong University, and \\[add additional participating institutions as applicable\\].",[26],"NOT_YET_RECRUITING","2026-05-21",{"date":133,"type":31},"2026-05-22",{"date":135,"type":21},"2026-05",{"date":137,"type":21},"2027-12",{"name":139,"class":38},"First Affiliated Hospital Xi'an Jiaotong University",{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":150,"conditions":151,"keywords":154,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":172},"100420927","annuloplasty-rings-and-band-post-market-clinical-follow-up-study-100420927","NCT04761120","Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study","Annuloplasty Rings and Band Post-Market Clinical Follow-Up (ARB-PMCF) Study","ARB-PMCF","Inclusion Criteria:\n\n1. Subject is expected to undergo cardiac surgery in ≤90 days including at least one of the following:\n\n   1. implant of a Rigid Saddle Ring, Séguin Ring or a full Tailor Ring without cut zone removal for MR repair\n   2. implant of a full Tailor Ring without cut zone removal for TR repair, or\n   3. implant of a Tailor Band or partial Tailor Ring with cut zone removed for primary TR repair.\n2. Subject's cardiac surgery will be performed by a study investigator.\n3. Subject will be ≥18 years old at the time of their annuloplasty implant(s).\n4. Subject provides written informed consent and agrees to comply with all required study visits and procedures.\n\nExclusion Criteria:\n\n1. Subject is below the age of legal consent in the applicable jurisdiction or otherwise lacks legal authority to provide informed consent.\n2. Subject is unable to read or write or has a mental illness or disability that impairs their ability to provide written informed consent.\n3. Subject is expected to have active endocarditis at the time of their Abbott annuloplasty device implant(s).\n4. Subject cannot be unambiguously assigned to a treatment group due to missing data on repair indication(s) or the model and configuration (cut zone removed or not) of their Abbott annuloplasty implant(s).\n5. Subject is participating in another clinical investigation including any treatment outside the investigative site's usual standard of care.\n6. Subject has anomalous anatomy or medical, surgical, psychiatric or social history or conditions that, in the investigator's opinion, would limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements",{"count":149,"type":21},550,"ARB-PMCF is a multicenter, observational study of the safety and performance of Abbott annuloplasty devices used in surgical repair of mitral and tricuspid valve regurgitation. The devices included in this study are the SJM™ Rigid Saddle Ring and SJM Séguin Annuloplasty Ring, indicated for mitral valve repair, and the SJM Tailor™ Annuloplasty Ring and SJM Tailor Annuloplasty Band, indicated for mitral or tricuspid repair. Participants will be enrolled prior to undergoing mitral or tricuspid valve repair surgery including an Abbott annuloplasty implant and will complete annual follow-up visits through five years from implant. The study is being conducted to meet post-market clinical follow-up requirements of the European Union Medical Device Directives.",[152,153,26],"Mitral Regurgitation","Tricuspid Regurgitation",[152,153,155,156,157,158,159,160,161,162],"Valve Surgery","Valve Repair","Annuloplasty Rings","Annuloplasty Bands","Rigid Saddle Ring","Séguin Annuloplasty Ring","Tailor Annuloplasty Ring","Tailor Annuloplasty Band","2026-05-14",{"date":165,"type":31},"2026-05-18",{"date":167,"type":31},"2021-02-01",{"date":169,"type":21},"2031-03",{"name":171,"class":117},"Abbott Medical Devices",17,{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":182,"phases":183,"briefSummary":185,"conditions":186,"keywords":187,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":39},"100522023","home-based-cardiac-rehabilitation-using-a-novel-mobile-health-exercise-regimen-following-transcatheter-heart-valve-interventions-100522023","NCT06077201","Home-Based Cardiac Rehabilitation Using a Novel Mobile Health Exercise Regimen Following Transcatheter Heart Valve Interventions","HOMERUNHITTER","Inclusion Criteria:\n\n* Treated with a transcatheter heart valve intervention (e.g., transcatheter aortic valve implantation \\[in the native valve or valve-in-valve\\], mitral transcatheter edge-to-edge repair, mitral valve-in-valve) of the aortic, mitral, or tricuspid valve done via transfemoral access\n\nExclusion Criteria:\n\n* Unwilling or unable to provide informed consent\n* Not adherent to wearing the ActiGraph activity tracker during the roll-in phase for a minimum of 4 (out of 7) compliant days (worn \\>10 hours\u002Fday)\n* Planned participation in center based cardiac rehabilitation (CBCR)\n* Transcatheter heart valve intervention done via any route other than a transfemoral approach\n* Stroke during or immediately after the transcatheter heart valve intervention prior to randomization\n* Placement of a pacemaker within 6 weeks prior to the transcatheter heart valve intervention or after the transcatheter heart valve intervention and prior to randomization\n* Those who require a walker or who cannot get out of a chair\u002Fbed on their own and walk independently (use of a cane is acceptable)\n* Physical or neuropsychiatric limitations that would prevent proficient use of the study tools and successful completion of the physical and quality of life assessments (e.g. blindness, dementia)\n* Planned surgery within 6 months after the heart valve intervention\n* Planned discharge from hospital to hospice, assisted living, or inpatient rehabilitation facility (discharge to a senior facility permitted as long as they are considered Independent Living)\n* Treating provider or site PI indicates that participation in the study would be unsafe\n* Participation in any ongoing randomized trial that has not completed follow-up unless the sponsor of the other trial allows enrollment of the participant in this cardiac rehabilitation trial\n* Unable to complete the baseline study visit prior to 6 weeks after the transcatheter heart valve intervention",{"count":181,"type":21},240,"INTERVENTIONAL",[184],"NA","The vast majority of cardiac rehabilitation eligible individuals do not participate in center based cardiac rehabilitation (CBCR). While steps to encourage participation in CBCR are important, many individuals will still not participate for a variety of reasons. This randomized controlled trial is evaluating a home-based cardiac rehabilitation (HBCR) intervention delivered using a custom app and digital tools in patients undergoing transcatheter heart valve interventions (THVIs). After a brief roll-in period, participants not intending to participate in CBCR are randomized to one of three groups: (1) control, (2) HBCR mobile health intervention with hands-off delivery, and (3) HBCR mobile health intervention with interactive delivery. Participants in the intervention groups (hands-off\u002Finteractive delivery) will also be randomized to continue the intervention for 12 weeks or 24 weeks. The intervention targets key health behaviors and includes traditional cardiac rehabilitation components. The study will assess the effect of the intervention on clinical events, physical activity, quality of life, and other outcomes. Those who intend to participate in CBCR will be followed in a registry.",[26],[188,189,190,191,192,193],"cardiac rehabilitation","transcatheter heart valve intervention","cardiology","aortic stenosis","mitral regurgitation","tricuspid regurgitation","2026-05-12",{"date":196,"type":31},"2026-05-15",{"date":198,"type":31},"2023-12-15",{"date":200,"type":21},"2026-10-01",{"name":202,"class":38},"Vanderbilt University Medical Center",{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":74,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":211,"targetDuration":212,"studyType":22,"phases":4,"briefSummary":213,"conditions":214,"keywords":222,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":39},"100489526","development-of-circ-technologies-100489526","NCT05654272","Development of CIRC Technologies","Development of Cardiovascular Innovation Research Technologies","CIRC","Inclusion Criteria:\n\n* Age ≥ 18 years of age\n* Provision of written informed consent\n* If not healthy volunteer, must be diagnosed with cardiovascular disease\n\nExclusion Criteria:\n\n* Vulnerable populations will be excluded from this study including Prisoners\n* Other contraindications to CMR imaging to be determined by standard MRI protocols\n* Decisionally impaired (e.g., dementia or cognitive disability)",{"count":48,"type":21},"20 Years","Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particularly beneficial. At the same time, blood work can be very useful in early detection of certain cardiomyopathy, such as amyloid. However, there is a lack of agreement of on which markers are the most sensitive. This multi-study will allow us the unique opportunity to form a more comprehensive understanding for various cardiovascular diseases.\n\nOur team has developed novel cardiac MRI techniques that leverages endogenous tissue properties to reveal a milieu of deep tissue phenotypes including myocardial inflammation, fibrosis, metabolism, and microstructural defects. Among these phenotypes, myocardial microstructure has proven to be most sensitive to early myocardial tissue damage and is predictive of myocardial regeneration. In this study, the investigators aim to further study the importance of cardiac microstructure revealed by MRI in patient and healthy population and compare this novel technology with conventional clinical biomarkers.",[215,84,85,216,26,217,218,219,220,221],"Cardiovascular Diseases","Non-ischemic Cardiomyopathy","Metabolic Cardiomyopathy","Congenital Heart Disease","Aortic Diseases","Atrial Fibrillation","Ventricular Fibrillation",[223],"MRI","2026-05-06",{"date":226,"type":31},"2026-05-08",{"date":228,"type":31},"2022-09-09",{"date":230,"type":21},"2042-09-09",{"name":232,"class":38},"The Cleveland Clinic",{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":182,"phases":243,"briefSummary":244,"conditions":245,"keywords":246,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":39},"100602588","comparing-measurements-of-the-aortic-valve-taken-during-surgery-with-those-obtained-before-surgery-using-computed-tomography-scans-in-patients-undergoing-surgical-aortic-valve-replacement-100602588","NCT07125469","Comparing Measurements of the Aortic Valve Taken During Surgery With Those Obtained Before Surgery Using Computed Tomography Scans, in Patients Undergoing Surgical Aortic Valve Replacement","Intraoperative Assessment Versus Preoperative Multidetector Computed Tomography (MDCT) for Aortic Valve Annular Sizing in Surgical Aortic Valve Replacement (SAVR)\"","SAVR-CT-AVA","Inclusion Criteria:\n\nPatient age 18 years or older\n\nAll patients with isolated severe Aortic Stenosis (AS) considered eligible for Surgical Aortic Valve Replacement (SAVR) according to the current 2023 European Society of Cardiology\u002FEuropean Association for Cardio-Thoracic Surgery (ESC\u002FEACTS) guidelines for management of Valvular Heart Disease (reference 8) will be enrolled.\n\nPatient is willing to comply with study procedures and is available to return to the center for follow-up visits.\n\nInformed consent documentation signed and dated confirming that the patient has been adequately informed of all aspects related to his\u002Fher participation in the clinical study and is willing to participate.\n\nExclusion Criteria:\n\nBicuspid aortic valve anatomy Moderate to severe aortic valve regurgitation Multivalvular disease Redo Surgical Aortic Valve Replacement Ascending aorta aneurysm Aortic root enlargement Chronic Kidney Disease with estimated Glomerular Filtration Rate less than 30 milliliters per minute Body Mass Index greater than 30 kilograms per square meter Inadequate Multidetector Computed Tomography images",{"count":242,"type":21},82,[184],"This study aims to understand why there may be differences between the measurements of the aortic valve taken before and during surgery. Specifically, it will compare the valve size suggested by a CT scan (Computed Tomography) with the size measured during the operation using surgical tools. This will help determine which method is more accurate for selecting the right valve size in patients undergoing SAVR (Surgical Aortic Valve Replacement ).",[26],[247],"valve size, Surgical Aortic Valve Replacement","2026-05-04",{"date":226,"type":31},{"date":251,"type":31},"2025-06-25",{"date":253,"type":21},"2026-12-31",{"name":255,"class":38},"Maria Cecilia Hospital",{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":263,"targetDuration":265,"studyType":22,"phases":4,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":274,"leadSponsor":276,"locationsCount":4},"100636510","spanish-prospective-registry-of-hydra-thv-for-transcatheter-aortic-valve-implantation-100636510","NCT07566624","Spanish Prospective Registry of Hydra THV for Transcatheter Aortic Valve Implantation","HYSPANIA","Inclusion Criteria:\n\nParticipants who meet ALL of the following conditions will be included:\n\n* Age ≥ 18 years and;\n* Severe aortic stenosis with indication for aortic valve replacement in which a Hydra THV device is implanted according to the instructions for use; and\n* Signed informed consent.\n\nExclusion Criteria:\n\nPatients who do NOT meet ANY of the following conditions will be included:\n\n* Express refusal by the participant to participate in the study.\n* Aortic stenosis patients who are not candidates for Hydra THV device implantation or in whom implantation of this device is performed for an indication other than aortic stenosis (especially pure native aortic valve insufficiency). Patients in whom the Hydra THV device is implanted to treat patients with degenerated aortic bioprostheses may be included in the study.\n* Participants in randomised clinical trials who have not reached the research endpoint.\n* Pregnant and\u002For breastfeeding women.",{"count":264,"type":21},100,"12 Months","This study is designed to evaluate the success rate of transfemoral implantation of the Hydra THV biological aortic valve prosthesis in patients with severe symptomatic aortic stenosis. The device is used in accordance with its Instructions for Use as a CE-marked transcatheter heart valve system.\n\nThe study will assess procedural success, device performance, and early clinical outcomes following implantation. Patients undergoing transcatheter aortic valve replacement (TAVR) via the transfemoral approach will be followed to evaluate safety and effectiveness outcomes, including short- and mid-term clinical follow-up.",[268,26,269],"Severe Aortic Valve Stenosis","Aortic Valve Stenosis","2026-04-27",{"date":272,"type":31},"2026-05-05",{"date":110,"type":21},{"date":275,"type":21},"2029-02-01",{"name":277,"class":38},"Fundación EPIC",{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":284,"eligibilityCriteria":285,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":288,"conditions":289,"keywords":295,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":39},"100608144","delineate-prospective-100608144","NCT07197736","DELINEATE-Prospective","Deep Learning for Echo Analysis, Tracking, and Evaluation Prospective Evaluation (DELINEATE-Prospective)","DELINEATE","Inclusion Criteria:\n\n* Attending cardiologist employed by Columbia University, ColumbiaDoctors, or NewYork Presbyterian Hospital who reads transthoracic echocardiograms in the Columbia echocardiography laboratory\n* Provided informed consent to take part in the questionnaires or pivotal study\n\nExclusion Criteria:\n\n* Physician in training (cardiology fellow or advanced imaging fellow)",{"count":287,"type":21},50,"Heart disease is the leading cause of death in the United States, and echocardiography (or \"echo\") is the most common way doctors look at the heart. Echo is safe, painless, and can detect major heart problems, including weak heart pumping and valve disease.\n\nValve disease, especially aortic stenosis (narrowing) and mitral regurgitation (leakage), is common in older adults but often goes undiagnosed. While echo is the main tool for finding valve problems, it takes time, requires expert training, and results can vary between readers.\n\nRecent advances in artificial intelligence (AI), especially deep learning (DL), have shown promise in automatically analyzing heart images. However, past research hasn't fully tackled key echo techniques-like color Doppler and spectral Doppler-that are crucial for measuring how blood moves through heart valves. AI tools also face challenges in being used in everyday medical practice because of workflow issues, lack of real-world testing, and concerns about how the algorithms make decisions.\n\nAt Columbia University Irving Medical Center, researchers have built a large database of heart tests over the last six years and developed AI programs to analyze echocardiograms. The current study will test whether providing AI analysis to cardiologists in real time during echo reading can make the process faster and more consistent.",[290,291,292,26,293,294],"Valve Disease, Aortic","Mitral Regurgitation (MR)","Aortic Stenosis","Tricuspid Regurgitation (TR)","Aortic Regurgitation",[296,297,53,298,299,192,191],"artificial intelligence","deep learning","echocardiography","cardiovascular disease","2026-04-14",{"date":302,"type":31},"2026-04-16",{"date":304,"type":21},"2026-04-15",{"date":306,"type":21},"2028-10-01",{"name":308,"class":38},"Columbia University",{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":318,"conditions":319,"keywords":325,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":353},"100561461","abbott-structural-heart-device-registry-100561461","NCT06590467","Abbott Structural Heart Device Registry","SH-Registry","Inclusion Criteria:\n\n1. Subject is expected to undergo an implant attempt using one or more Abbott Structural Heart devices covered in this Registry or has previously undergone an implant attempt within the timeframes specified in the device-specific appendices.\n2. Subject is willing and able to comply with the site's standard of care follow-up schedule.\n3. Subject is willing to provide appropriate informed consent for Registry participation. For deceased subjects enrolled retrospectively, local regulations and EC\u002FIRB recommendations regarding consent and the protection of personal data must be followed.\n\nExclusion Criteria:\n\n1\\. Subject is participating in another clinical study that would affect the results of this Registry.",{"count":317,"type":21},2500,"The Abbott Structural Heart (SH) Registry is being conducted to confirm the safety and performance of Abbott's SH devices in a post-market, real-world setting. The Registry primarily involves gathering data from routine hospital practices and standard-of-care (SOC) procedures administered to patients. All devices used in these procedures must be commercially available to the participating site. A list of specific devices covered by the Registry are available upon request from the Sponsor. Data generated by the Registry will be used to meet regulatory requirements, such as the European Union Medical Device Regulations 2017\u002F745, that require active post-market clinical follow-up (PMCF) for all commercially available devices.",[320,321,322,323,324,26],"Heart Diseases","ASD - Atrial Septal Defect","VSD - Muscular Ventricular Septal Defect","PFO - Patent Foramen Ovale","PIVSD - Post Infarct Muscular Ventricular Septal Defect",[326,327,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344],"Amplatzer","Amplatzer Septal Occluder","Amplatzer Multi-fenestrated (Cribriform) Occluder","Amplatzer Duct Occluder","Amplatzer Piccolo Occluder","Amplatzer Muscular VSD Occluder","Amplatzer Post-Infarct VSD Occluder","Amplatzer Talisman","Amplatzer TorqVue Delivery System","Amplatzer Sizing Balloon","Amplatzer Guidewire","Amplatzer Occluder devices","Surgical Valves","Epic Plus Aortic Valve","Epic Plus Mitral Valve","Epic Plus Supra Aortic Valve","Epic Max Aortic Valve","Bioprosthetic heart valve","Surgical tissue heart valve","2026-04-07",{"date":347,"type":31},"2026-04-13",{"date":349,"type":31},"2024-08-21",{"date":351,"type":21},"2039-11",{"name":171,"class":117},28,{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":74,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":364,"conditions":365,"keywords":367,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":4},"100631138","cardiovascular-acoustics-for-early-disease-detection-100631138","NCT07496775","Cardiovascular Acoustics for Early Disease Detection","ACOUTECT: Cardiovascular Acoustics for Early Disease Detection","ACOUTECT","Inclusion Criteria:\n\n* Participants aged ≥18 years\n* Able to provide written, informed consent\n* Has undergone angiography in the previous 6 months and scheduled to undergo transthoracic echocardiography, or has undergone transthoracic echocardiography in the previous 6 months and scheduled to undergo angiography, or is scheduled to undergo transthoracic echocardiography and angiography within 6 months.\n* Angiography and echocardiography performed within Cambridge University Hospitals NHS Foundation Trust.\n\nExclusion Criteria:\n\n* Haemodynamic instability\n* STEMI or high risk NSTEMI\n* Anginal symptoms at rest\n* Heart failure symptoms with NYHA 4\n* Cardiovascular related admission or event occurring between imaging studies\n* Uncontrolled symptomatic arrhythmia\n* Acute pulmonary embolism\n* Acute aortic dissection\n* Previous valve intervention\n* Suspected endocarditis",{"count":363,"type":21},500,"There are many types of heart disease. Two of the most common causes are narrowings within the blood vessels that supply the heart (known as coronary artery disease), or valves within the heart becoming narrowed (stenosed) or leaky (regurgitation), known as heart valve disease.\n\nThere are two main types of imaging used to test for these conditions. Coronary artery disease can be diagnosed by taking X-ray pictures of a dye when injected into the blood vessels. In some cases the dye is injected into the veins and a CT scanner is used (CT coronary angiography), in others the dye is injected via a tube placed in the artery (invasive coronary angiography). Valvular heart disease is normally diagnosed using an echocardiogram (ultrasound of the heart).\n\nIn this study the investigators are looking for subtle changes in the sounds that come from the heart, which may allow heart disease to be detected earlier. The investigators are using a novel device, similar to a digital stethoscope, that has excellent sensitivity for heart sounds. Ultimately this may be used in community settings including GP surgeries, in this study the investigators are collecting sounds from patients undergoing routine scans as part of their workup for heart disease.",[26,366],"Coronary Artery Disease",[368,53,369,370,371,372],"coronary artery disease","ischemic heart disease","cardiovascular acoustics","heart sounds","cardiac auscultation","2026-03-27",{"date":375,"type":31},"2026-04-01",{"date":377,"type":21},"2026-05-01",{"date":379,"type":21},"2029-12-31",{"name":381,"class":38},"Cambridge University Hospitals NHS Foundation Trust",{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":74,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":389,"conditions":390,"keywords":391,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":4},"100599224","longitudinal-validation-of-circ-technologies-100599224","NCT07081711","Longitudinal Validation of CIRC Technologies","Inclusion Criteria:\n\n* Age ≥ 18 years of age\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Vulnerable populations will be excluded from this study including Prisoners\n* Other contraindications to CMR imaging to be determined by standard MRI protocols\n* Decisionally impaired (e.g., dementia or cognitive disability)",{"count":48,"type":21},"Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particularly beneficial. At the same time, blood work can be very useful in early detection of certain cardiomyopathy, such as amyloid. However, there is a lack of agreement of on which markers are the most sensitive. This multi-study will allow the unique opportunity to form a more comprehensive understanding for various cardiovascular diseases.\n\nThe study team has developed novel cardiac MRI techniques that leverages endogenous tissue properties to reveal a milieu of deep tissue phenotypes including myocardial inflammation, fibrosis, metabolism, and microstructural defects. Among these phenotypes, myocardial microstructure has proven to be most sensitive to early myocardial tissue damage and is predictive of myocardial regeneration. In this study, the investigators aim to further study the importance of cardiac microstructure revealed by MRI in patient and healthy population and compare this novel technology with conventional clinical biomarkers.",[215,84,85,216,26,217,218,219,220,221],[223],"2026-03-19",{"date":394,"type":31},"2026-03-23",{"date":396,"type":21},"2026-04",{"date":398,"type":21},"2037-08",{"name":232,"class":38},{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":74,"sex":17,"minAge":18,"maxAge":407,"enrollmentInfo":408,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":409,"conditions":410,"keywords":413,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":425},"100427235","ppg-to-predict-ejection-fraction-and-other-echographic-data-in-the-general-population-100427235","NCT04843371","PPG to Predict Ejection Fraction and Other Echographic Data in the General Population","Photoplethysmography (PPG) to Predict Ejection Fraction and Other Echographic Data in the General Population","Inclusion Criteria:\n\n* Male or Female aged18 years or older.\n* Patients scheduled to undergo an echocardiogram at Tulane Medical Center.\n\nExclusion Criteria:\n\n* Participants under 18 years of age.\n* Participants with cognitive impairments.\n* Participants with a physical inability to wear the Biostrap during the echocardiogram.\n* Individuals who cannot read, speak, and\u002For understand English.","120 Years",{"count":363,"type":21},"The investigators are aiming to investigate the association between ejection fraction (EF) determined by echocardiography and signals obtained from Photoplethysmography (PPG) in the general population. The investigators are also aiming to investigate the association between blood pressure and signals obtained from PPG in the general population.\n\nFinally, the investigators are also aiming to investigate the association between signals obtained from PPG in the general population to cardioechographic findings such as, valvular heart disease, structural heart diseases, cardiomyopathies, pericardial disease etc.",[26,411,412],"Pericardial Disease","Cardiomyopathies",[414,415,105],"Structural heart disease","Photoplethysmography","2026-03-03",{"date":418,"type":31},"2026-03-05",{"date":420,"type":31},"2021-08-20",{"date":422,"type":21},"2026-12",{"name":424,"class":38},"Tulane University",3,{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":182,"phases":436,"briefSummary":437,"conditions":438,"keywords":440,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":456},"100596213","optimized-expansion-of-the-implanted-transcatheter-aortic-valve-100596213","NCT07042529","Optimized Expansion of the Implanted Transcatheter Aortic Valve","Optimized Expansion of the Implanted Transcatheter Aortic Valve to Reduce Hypoattenuating Leaflet Thickening in Non-atrial Fibrillation Patients Undergoing Transcatheter Aortic Valve Implantation: an International, Multicentre, Randomized Controlled Trial","OptEx-TAVI","Inclusion Criteria:\n\n* Severe symptomatic aortic stenosis patients with an indication for TAVI\n* Ability to understand and to comply with the study protocol\n\nExclusion Criteria:\n\n* Existing indication for oral anticoagulation (e.g., atrial fibrillation, venous thromboembolism, antiphospholipid syndrome, mechanical mitral valve)\n* Creatinine clearance \\\u003C15 mL\u002Fmin (CKD-EPI formula) or on renal replacement therapy\n* Iodine contrast allergy or other condition that prohibits cardiac CT imaging",{"count":435,"type":21},620,[184],"Optimized Expansion of the implanted transcatheter aortic valve to reduce hypoattenuating leaflet thickening in non-atrial fibrillation patients undergoing transcatheter aortic valve implantation (TAVI): an international, multicentre, randomized controlled trial.\n\nThe objective is to evaluate whether TAVI with systematic optimized pre- and post-dilatation (optimized expansion (OptEx) TAVI strategy), compared to a standard of care (SoC) TAVI strategy, is superior in reducing hypoattenuating leaflet thickening as evaluated by cardiac computed tomography (CT) imaging at three months after TAVI.\n\nThe primary outcome is at least one thickened TAV leaflet involving ≥ 25% of the leaflet curvilinear dimension as assessed at cardiac CT at three months after TAVI.",[439,26],"Aortic Stenosis Disease",[441,442,443,444,445,446],"Aortic stenosis","Cardiovascular","Transcatheter aortic valve","Transcatheter aortic valve implantation","Valvular heart disease","TAVI","2026-02-01",{"date":449,"type":31},"2026-02-03",{"date":451,"type":31},"2025-10-05",{"date":453,"type":21},"2033-07-01",{"name":455,"class":38},"Ole De Backer",10,{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":463,"enrollmentInfo":464,"targetDuration":265,"studyType":22,"phases":4,"briefSummary":465,"conditions":466,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":39},"100567995","in-search-of-best-practices-for-patients-with-heart-failure-and-secondary-mitral-regurgitation-an-evaluation-of-the-inova-heart-failure-treatment-algorithm-100567995","NCT06675448","In Search of Best Practices for Patients With Heart Failure and Secondary Mitral Regurgitation: An Evaluation of the Inova Heart Failure Treatment Algorithm","Inclusion Criteria:\n\n* Symptomatic MR (≥2+) due to cardiomyopathy of either ischemic or nonischemic etiology\n* Subject has been adequately treated per applicable standards, including for coronary artery disease, LV dysfunction, MR, and HF.\n* NYHA functional class II, III, or ambulatory IV\n* Local heart team has determined that MV surgery will not be offered as a treatment option even if the subject is randomized to the Control group.\n* LVEF ≤50%.\n* LVESD ≤70 mm\n* The primary regurgitant jet , in the opinion of the MitraClip implanting investigator, can be successfully treated by the MitraClip (if a secondary jet exists, it must be considered clinically insignificant).\n* Transseptal catheterization and femoral vein access is feasible per the MitraClip implanting investigator.\n* Age 18 y or older\n* Subject or guardian agrees to all provisions of the protocol\n* NT-proBNP≥ 1500ng\u002Fml or BNP≥ 300ng\u002Fml\n\nExclusion Criteria:\n\n* Untreated clinically significant coronary artery disease requiring revascularization\n* CABG, PCI, or TAVR within the prior 30 d\n* Aortic or tricuspid valve disease requiring surgery or transcatheter intervention\n* COPD requiring continuous home oxygen therapy or chronic outpatient oral steroid use\n* Cerebrovascular accident within prior 30 d\n* Severe symptomatic carotid stenosis (N70% by ultrasound)\n* Carotid surgery or stenting within prior 30 d\n* ACC\u002FAHA stage D HF\n* Presence of any of the following:\n* Estimated PASP N70 mm Hg assessed by site based on echocardiography or right heart catheterization, unless active vasodilator therapy in the catheterization laboratory is able to reduce the PVR to b3 Wood units or between 3 and 4.5 Wood units with v wave less than twice the mean of the PCWP\n* Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing HF other than dilated cardiomyopathy of either ischemic or nonischemic etiology\n* Infiltrative cardiomyopathies (eg, amyloidosis, hemochromatosis, sarcoidosis)\n* Hemodynamic instability requiring inotropic support or mechanical heart assistance\n* Physical evidence of right-sided congestive HF with echocardiographic evidence of moderate or severe right ventricular dysfunction\n* Implant of CRT or CRT-D within the last 30 d\n* Mitral valve orifice area \\\u003C4.0 cm2 by site-assessed TTE\n* Leaflet anatomy which may preclude MitraClip implantation, proper MitraClip positioning on the leaflets, or sufficient reduction in MR by the MitraClip\n* Hemodynamic instability defined as persistent systolic pressure \\\u003C90 mm Hg with or without afterload reduction, cardiogenic shock, or the need for inotropic support or intra-aortic balloon pump or other hemodynamic support device\n* Need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 m\n* Life expectancy \\\u003C12 m due to noncardiac conditions\n* Investigators opinion a condition that could limit the subject's participation\n* Status 1 heart transplant or prior orthotopic heart transplantation\n* Prior mitral valve leaflet surgery or any currently implanted prosthetic mitral valve, or any prior transcatheter mitral valve procedure\n* Echocardiographic evidence of intracardiac mass, thrombus, or vegetation\n* Active endocarditis or active rheumatic heart disease or leaflets degenerated from rheumatic disease (ie, noncompliant, perforated)\n* Active infections requiring current antibiotic therapy\n* TEE is contraindicated or high risk\n* Known hypersensitivity or contraindication to procedural medications which cannot be adequately managed medically\n* Pregnant or planning pregnancy within next 12m\n* Currently participating in an investigational drug or another device study that has not reached its primary end point\n* Subject belongs to a vulnerable population or has any disorder that compromises his\u002Fher ability to give written informed consent and\u002For to comply with study procedures.","99 Years",{"count":287,"type":21},"The overarching goal of this research proposal is to study the feasibility and clinical impact of implementing an Inova system-wide heart failure treatment algorithm for patients with symptomatic heart failure due to reduced left ventricular ejection fraction (HFreF) and secondary MR\n\nAim is to check the effectiveness of the IHFTA in identifying patients who are most likely to benefit from percutaneous transcatheter Mitraclip repair in real world",[152,26,84],"2025-12-01",{"date":469,"type":31},"2025-12-03",{"date":471,"type":31},"2021-01-28",{"date":473,"type":21},"2030-09-10",{"name":475,"class":38},"Inova Health Care Services",{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":17,"minAge":212,"maxAge":4,"enrollmentInfo":482,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":484,"conditions":485,"keywords":487,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":39},"100472337","comparison-of-post-operation-cardiopulmonary-capacity-of-patients-underwent-conventional-and-robot-assisted-coronary-artery-bypass-graft-and-valve-replacement-surgery-100472337","NCT05430568","Comparison of Post-operation Cardiopulmonary Capacity of Patients Underwent Conventional and Robot-assisted Coronary Artery Bypass Graft and Valve Replacement Surgery","Inclusion Criteria:\n\n* patient who undergo surgery for coronary artery bypass graft or valvular replacement.\n\nExclusion Criteria:\n\n* pregnant\n* patients who receive more than one type of surgery\n* severe complications after surgery (ex. respiratory failure, stroke) and stayed in hospital for more than 2 weeks.\n* cannot perform the cardiopulmonary exercise testing\n* other contraindications for cardiopulmonary exercise testing",{"count":483,"type":21},80,"Robotic surgery is one of the most popular minimally invasive procedures for patients with coronary artery disease or valvular diseases. Studies have shown that, as compared to conventional sternotomy, patients underwent robot-assisted bypass grafting or valvuloplasty had less post-operation pain, blood transfusion volume during operation, re-operation rate, post-operation stroke rate and length of hospitalization. However, most studies focused on the comparison of complications of different procedures, and the investigation of cardiopulmonary function recovery is still lacking. Thus our study is to compare the functional outcomes between patients that undergo different surgical procedures.",[486,26],"Coronary Bypass Graft Stenosis",[488,489,490],"cardiorespiratory fitness","robotic assisted surgery","cardiopulmonary exercise testing","2025-09-02",{"date":493,"type":31},"2025-09-09",{"date":495,"type":21},"2025-11-01",{"date":497,"type":21},"2028-05-31",{"name":499,"class":38},"Taichung Veterans General Hospital",{"id":501,"slug":502,"hasResults":12,"nctId":503,"briefTitle":504,"officialTitle":505,"acronym":506,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":508,"targetDuration":49,"studyType":22,"phases":4,"briefSummary":510,"conditions":511,"keywords":512,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":39},"100597977","mechanism-and-effect-of-novel-metabolites-on-valvular-heart-disease-100597977","NCT07065500","Mechanism and Effect of Novel Metabolites on Valvular Heart Disease","Mechanism and Effect of Novel Metabolites on Valvular Heart Disease（Hestia Study）","Hestia","Inclusion Criteria:\n\n1. Age ≥18 years, gender is not limited.\n2. Clinical diagnosis of heart valve disease (including aortic stenosis, aortic valve closure insufficiency due to different etiologies, mitral stenosis, mitral valve closure insufficiency, pulmonic stenosis, pulmonic valve closure insufficiency, tricuspid stenosis and tricuspid closure insufficiency due to different etiologies )\n\nExclusion Criteria:\n\nPatients unable to provide informed consent",{"count":509,"type":21},4000,"Valvular heart disease (VHD) is a leading cause of loss of physical function, reduced quality of life and increased longevity.The epidemiology of VHD varies widely across the globe, with functional and degenerative diseases occurring predominantly in high-income countries and rheumatic heart disease occurring predominantly in low- and middle-income countries. The prevalence of valvular heart disease (VHD) is increasing globally due to improved survival and aging populations, poorly controlled by medications, with the majority of patients having to undergo surgical or interventional treatments.\n\nIt is therefore important to search for novel metabolites and conduct mechanistic studies on the effects of these metabolites on patients with heart valve disease.\n\nIn the Hestia study, the investigators looked for risk factors and mechanisms associated with the development and prognosis of VHD through long-term follow-up of VHD patients and metabolite testing of specimen tissues.",[26],[513,53,514,515],"novel metabolites","prognosis","Risk Factors","2025-08-29",{"date":491,"type":31},{"date":519,"type":31},"2025-08-01",{"date":521,"type":21},"2030-03-01",{"name":523,"class":38},"Sun Yat-sen University",{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":74,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":533,"conditions":534,"keywords":536,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":545,"locationsCount":39},"100600586","screening-of-valvular-heart-disease-using-single-channel-electrocardiogram-100600586","NCT07099417","Screening of Valvular Heart Disease Using Single-channel Electrocardiogram","Screening of Valvular Heart Disease Using Single-channel Electrocardiogram Analyzed With Machine Learning Models","Inclusion Criteria:\n\n* The presence of written informed consent of the patient to participate in the study\n* Age from 18 years\n* Outpatient treatment and \u002F or hospitalization in a research center\n\nExclusion Criteria:\n\n* Reluctance of the patient to participate in the study\n* Poor quality ECG recording on a single-channel ECG monitor\n* Poor visualization of the heart during echocardiographic study\n* Acute psychotic reactions that arose during research\n* An exacerbation of chronic diseases requiring treatment tactics for the patient and preventing his further participation in the study.\n\nNon-inclusion criteria:\n\n* Poor quality ECG recording on a single-channel ECG monitor\n* Conditions that can impair ECG recording quality (Parkinson's disease, essential tremor)\n* Mental illness\n* Patients with a pacemaker installed\n* Patients with prosthetic valves",{"count":532,"type":21},1200,"It is a prospective, controlled, single-center, observational, non-randomized study. The study is planned to include at least 1000 patients over 18 years old in the training sample and 200 patients over 18 years old in the test sample (the total number of patients is at least 1200 people).\n\nAll patients will undergo an echocardiography examination with a comprehensive analysis of the function of the valves and other structures of the heart according to current recommendations by two independent experts.\n\nRegistration of electrocardiogram will be performed immediately after echocardiography using a single lead ECG monitor (in I standard lead) for 1 minutes.\n\nThe obtained data will be stored in the remote monitoring center of Sechenov University without being linked to the personal data of patients.\n\nA spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform.\n\nThe result of this study will be the identification of ECG parameters that will correlate with valvular heart disease.",[535,26],"Valvular Heart Disease Stenosis and Regurgitation",[53,537,538,539],"Screening","single-channel electrocardiogram","machine learning models","2025-07-25",{"date":519,"type":31},{"date":543,"type":31},"2025-01-01",{"date":253,"type":21},{"name":546,"class":38},"I.M. Sechenov First Moscow State Medical University",{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":74,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":556,"conditions":557,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":566,"locationsCount":425},"100591729","vibrometer-based-pulse-wave-analysis-for-arterial-stiffness-and-ischemic-heart-disease-risk-assessment-100591729","NCT06984211","Vibrometer Based Pulse Wave Analysis for Arterial Stiffness and Ischemic Heart Disease Risk Assessment","Cardio Alpha - Vibrometer Based Pulse Wave Analysis for Arterial Stiffness and Ischemic Heart Disease Risk Assessment","Inclusion criteria:\n\n* Adult patients that are part of the regular healthcare patient flow at the investigational sites, or as separately invited to participate in this investigation.\n* Patients with signed informed consent\n\nExclusion criteria:\n\n* Cognitive impairment\n* Patients unable to understand the oral and written study information in Swedish or English\n* Other severe disorder or terminal disease, e.g. infection\u002Fsepsis, severe COPD or metastatic cancers.\n* Patients unable to provide an informed consent",{"count":555,"type":21},8000,"This clinical investigation will evaluate a novel contactless technology for assessing arterial stiffness and explore its potential in assessment of risk for and development of cardiovascular disease.\n\nThe main aims of the study are:\n\n1. To assess device and method performance for assessment of arterial stiffness and cardiovascular risk, on a prospective primary care cohort.\n2. To see if precision may be added in CVD risk assessment through a multi-modal approach, combining data on macro- and micro-circulatory function.",[558,85,26,84,559],"Hypertension","Diabetes","2025-05-19",{"date":562,"type":31},"2025-05-22",{"date":564,"type":31},"2023-02-01",{"date":447,"type":21},{"name":567,"class":117},"HJN Sverige AB\u002FNeko Health",{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":575,"targetDuration":577,"studyType":22,"phases":4,"briefSummary":578,"conditions":579,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":39},"100588110","evaluation-of-valvular-heart-disease-using-cardiac-ct-100588110","NCT06937125","Evaluation of Valvular Heart Disease Using Cardiac CT","Evaluation of Valvular Heart Disease: Multicenter Registry of Noninvasive Imaging Modalities by Cardiac CT","Inclusion Criteria:\n\n* Patients with at least moderate valvular heart disease who had a cardiac CT with 64 or more rows\n* 18 years of age or older\n\nExclusion Criteria:\n\n* Less than 18 years old\n* Acute VHD\n* Infectious endocarditis\n* Patients with post-VHD intervention\n* Poor CT image quality for analyzing CT data.",{"count":576,"type":21},350,"1 Year","The EVIDENTIA Registry is a multicenter study designed to evaluate valvular heart disease (VHD) using cardiac CT. It aims to assess cardiac valve anatomy, function, and myocardial characteristics through detailed CT analysis.\n\n1. Assessing the accuracy of cardiac CT in evaluating cardiac structure, volume, function, and myocardium in VHD patients.\n2. Comparing the severity, classification, and etiology (primary vs. functional) of VHD.\n3. Monitoring serial changes in VHD severity via echocardiography.\n4. Investigating the relationship between echocardiographic and CT-derived parameters.\n5. Examining the correlation between imaging findings, VHD interventions, and patient prognosis.",[26],"2025-05-11",{"date":582,"type":31},"2025-05-14",{"date":584,"type":31},"2025-03-12",{"date":586,"type":21},"2028-03",{"name":588,"class":38},"Toho University",{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":595,"eligibilityCriteria":596,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":597,"targetDuration":4,"studyType":182,"phases":598,"briefSummary":599,"conditions":600,"keywords":602,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":616},"100515793","study-on-optimal-temperature-during-cardiopulmonary-bypass-thermic-4-100515793","NCT05996120","Study on Optimal Temperature During Cardiopulmonary Bypass (THERMIC-4)","Normothermic Versus Hypothermic Cardiopulmonary Bypass in Adult Cardiac Surgery: a Multicentre Feasibility Randomised Controlled Trial","THERMIC-4","INCLUSION CRITERIA\n\nParticipants may enter the trial if all of the following apply\n\n1. Adult patients (≥ 18 years) scheduled for coronary artery bypass surgery and\u002For valve replacement\u002F repair, either in the elective or urgent setting.\n2. European System for Cardiac Operative Risk Evaluation (EuroSCORE) II of 2 or higher.\n3. Able to understand and communicate to provide informed consent.\n4. Able to read and understand the English language.\n\nEXCLUSION CRITERIA\n\nParticipants may not enter the trial if any of the following apply:\n\n1. Patients undergoing coronary artery bypass surgery in combination with other procedures including cardiac or vascular procedures that require deep hypothermic arrest.\n2. Patients undergoing emergency or salvage surgery.\n3. Patients undergoing off-pump cardiac surgery.\n4. Patients who are participating in another interventional trial.\n5. Unable to provide informed consent.",{"count":264,"type":21},[184],"In order to perform heart surgery, a machine called cardiopulmonary bypass (CPB), or more commonly known as a heart-lung machine, is used to maintain the circulation of oxygenated blood needed by the rest of the body and its organs.\n\nHistorically, when a patient is connected to CPB, their body is cooled below the normal body temperature. This is known as hypothermia. This is because scientific studies have previously shown that reduced body temperature lowers metabolism and therefore offers more protection to the brain and other organs due to the reduced oxygen requirement. The evidence supporting this practice, however, has been challenged throughout the history of cardiac surgery, with studies supporting that normothermia, or normal body temperature, is a safe alternative. Despite this, the practice of hypothermia has persisted. Published data from a survey of 139 cardiac surgeons in the United Kingdom showed that 84% still routinely employ hypothermic CPB during surgery.\n\nTo assess whether normothermic or hypothermic CPB is safer, a clinical trial requiring a large sample size and high recruitment rates will be required. Therefore, the investigators aim to assess firstly the feasibility of trial recruitment and allocation adherence in this study. 100 adults across 10 different cardiac surgery centres in the United Kingdom will be recruited to a multicentre feasibility randomised controlled trial comparing normothermia (active comparator) against hypothermia (control comparator) during cardiopulmonary bypass in cardiac surgery. This study will also test the ability of the Cardiothoracic Interdisciplinary Research Network (CIRN), a trainee-led research collaborative, to collect pilot data on Major Adverse Cardiac and Cerebrovascular Events (MACCE) using a regulation-approved electronic application HealthBitⓇ. Participants will also be asked to complete quality of life surveys. The results of this study will subsequently inform a large, adequately powered randomised controlled trial for optimal temperature management during CPB.",[85,26,215,601],"Surgery-Complications",[603,604,605,606],"cardiopulmonary bypass","hypothermia","myocardial protection","neurologic protection","2025-03-31",{"date":609,"type":31},"2025-04-03",{"date":611,"type":31},"2024-05-20",{"date":613,"type":21},"2026-02",{"name":615,"class":38},"University of Leicester",11,{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":622,"acronym":623,"eligibilityCriteria":624,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":625,"targetDuration":4,"studyType":182,"phases":627,"briefSummary":628,"conditions":629,"keywords":630,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":634,"lastUpdatePostDateStruct":635,"startDateStruct":637,"completionDateStruct":639,"leadSponsor":641,"locationsCount":39},"100564818","efficacy-of-mitraclip-vs-pascal-for-the-treatment-of-mitral-regurgitation-in-an-all-comer-population-100564818","NCT06634121","Efficacy of MitraCLip Vs. PASCAL for the TrEAtment of MitraL REgurgiTation in an All-comer Population","Efficacy of Mitraclip Vs. PASCAL for the Treatment of Mitral Regurgitation in an All-comer Population","LEAFLET I","Inclusion Criteria:\n\n* Age equal or above 18 years\n* Written consent\n* Heart Team recommends M-TEER\n\nExclusion Criteria:\n\n* Mitral Stenosis (MV mean PG \\> 5 mmHg)\n* Cardiogenic shock or hemodynamic instability at the time of intervention\n* Active endocarditis\n* Participant in another interventional cardiology study",{"count":626,"type":21},180,[184],"To investigate potential differences in procedural outcomes of both commercially available transcatheter edge-to-edge mitral valve repair devices in a non-selected clinical setting.",[152,26,84],[152,631,632,633],"TEER","MitraClip","PASCAL","2024-10-08",{"date":636,"type":31},"2024-10-09",{"date":638,"type":31},"2024-04-01",{"date":640,"type":21},"2028-04-01",{"name":642,"class":38},"LMU Klinikum",{"id":644,"slug":645,"hasResults":12,"nctId":646,"briefTitle":647,"officialTitle":648,"acronym":4,"eligibilityCriteria":649,"healthyVolunteers":74,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":650,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":652,"conditions":653,"keywords":656,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":658,"lastUpdatePostDateStruct":659,"startDateStruct":661,"completionDateStruct":663,"leadSponsor":665,"locationsCount":39},"100561573","a-foundational-model-for-cardiovascular-disease-diagnosis-and-prediction-100561573","NCT06591923","a Foundational Model for Cardiovascular Disease Diagnosis and Prediction","Development and Clinical Application of a Foundational Model for Cardiovascular Disease Diagnosis and Prediction Based on Multimodal Medical Big Data","Inclusion Criteria:\n\nAge ≥ 18 years: Patients who are 18 years of age or older. Time period: Patients who were treated or diagnosed between January 1, 2009, and December 31, 2023.\n\nComplete medical records: Patients with comprehensive medical records, including ECG, echocardiography, MRI, CTA, nuclear imaging (SPECT\u002FPET), and biochemical test results.\n\nCardiovascular diseases: Patients with diagnosed cardiovascular conditions, such as coronary artery disease (CAD), heart failure, arrhythmias, and valvular heart disease (VHD), as well as healthy individuals for comparison.\n\nWillingness to participate: Patients who are able to provide informed consent or their legal representatives.\n\nExclusion Criteria:\n\nParticipation in other clinical trials: Patients who are currently participating in other clinical trials that may affect the study outcomes.\n\nIncomplete medical records: Patients whose medical records lack essential data, such as ECG, echocardiography, MRI, CTA, nuclear imaging (SPECT\u002FPET), or biochemical test results.\n\nData quality issues: Patients with records that have significant errors, inconsistencies, or incomplete data that cannot be reasonably corrected.\n\nEthical or legal concerns: Patients whose data cannot be used due to a lack of necessary consent or legal\u002Fethical restrictions.",{"count":651,"type":21},1000000,"The goal of this observational study is to develop and evaluate the efficacy of a foundational model that integrates multimodal medical data to improve the diagnosis and prediction of cardiovascular diseases in patients aged 18 and older, including those with various heart conditions such as coronary artery disease, heart failure, and arrhythmias. The main questions it aims to answer are:\n\nCan a multimodal data-based diagnostic model match or exceed the accuracy of traditional gold-standard methods like coronary angiography, MRI, and echocardiography? Does integrating different types of data (ECG, imaging, biochemical tests) improve diagnostic accuracy and prediction of cardiovascular disease outcomes? Researchers will compare the foundational model with traditional diagnostic methods to see if the model offers better sensitivity, specificity, and prediction accuracy across different heart disease types.\n\nParticipants will:\n\nProvide data from past medical records, including ECG, echocardiography, cardiac MRI, and biochemical tests.\n\nUndergo further data collection if necessary, in line with standard clinical procedures for cardiovascular disease management.",[654,84,655,26],"Coronary Heart Disease (CHD)","Arrhythmias",[657,296],"foundation model","2024-09-08",{"date":660,"type":31},"2024-09-19",{"date":662,"type":21},"2024-10",{"date":664,"type":21},"2025-04",{"name":666,"class":38},"Shanghai Zhongshan Hospital",{"id":668,"slug":669,"hasResults":12,"nctId":670,"briefTitle":671,"officialTitle":672,"acronym":673,"eligibilityCriteria":674,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":675,"targetDuration":265,"studyType":22,"phases":4,"briefSummary":677,"conditions":678,"keywords":680,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":684,"lastUpdatePostDateStruct":685,"startDateStruct":687,"completionDateStruct":689,"leadSponsor":691,"locationsCount":39},"100483358","novel-echocardiographic-biomarkers-assessing-the-myocardial-work-in-heart-failure-100483358","NCT05573997","Novel Echocardiographic Biomarkers Assessing the Myocardial Work in Heart Failure","Clinical Value of Novel Echocardiographic Biomarkers Assessing the Myocardial Work in Heart Failure","Beyond-MyoHF","Inclusion Criteria:\n\n1. Patients acutely admitted at the Department of Cardiology of AHEPA University General Hospital, Thessaloniki, Greece with symptoms and\u002For signs of heart failure (HF), as those are defined by the European Society of Cardiology.\n2. Patients with abnormal plasma concentration of N-terminal pro-B-type natriuretic peptide, measured within 24 hours from admission\n3. Objective echocardiographic evidence of cardiac structural and\u002For functional abnormalities consistent with the presence of left ventricular (LV) systolic dysfunction\u002Fdiastolic dysfunction\u002Fraised LV filling pressures upon admission assessment\n\nExclusion Criteria:\n\n1. Symptoms and\u002For signs of HF secondary to congenital heart disease, infective endocarditis, pericardial disease, and history of recent cardiac surgery (\\\u003C1 month)\n2. Patients receiving maintenance hemodialysis\n3. Patients with active malignancy and\u002For life expectancy \\\u003C 1 year\n4. Poor echocardiographic acoustic windows precluding reliable assessment and\u002For analysis\n5. Heart transplantation\n6. Patients not providing informed written consent to participate in the study",{"count":676,"type":21},300,"This study seeks to investigate the clinical value of novel echocardiographic indices, including myocardial work parameters, during the acute phase of heart failure hospitalization. The trajectory of novel echocardiographic indices from the start to the end of hospitalization will be captured, as a means to unravel and subsequently better understand the diverse pathophysiology of different phenotypes of the heart failure continuum. Correlation between novel echocardiographic indices with clinical data, biochemical data, different heart failure phenotypes, and therapeutic maneuvers will be attempted. Prognostic implications of those indices will be explored.",[215,84,26,679],"Biochemical Dysfunction",[84,681,682,683],"Echocardiography","Myocardial Work","Functional Valvular Heart Disease","2024-07-30",{"date":686,"type":31},"2024-07-31",{"date":688,"type":31},"2022-04-10",{"date":690,"type":21},"2025-01-10",{"name":692,"class":38},"Aristotle University Of Thessaloniki"]